Previous 10 |
home / stock / wuxay / wuxay news
WuXi AppTec Receives AA ESG Rating from MSCI WuXi AppTec upgraded to an AA environmental, social and governance (ESG) rating by Morgan Stanley Capital International PR Newswire SHANGHAI , Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleas...
WuXi AppTec (WUXAY): Q1 Non-GAAP EPS of RMB0.38; GAAP EPS of RMB0.61.Revenue of RMB4.95B (+55.3% Y/Y)Press Release For further details see: WuXi AppTec reports Q1 results
WuXi AppTec (WUXAY): FY Non-GAAP EPS of RMB1.51; GAAP EPS of RMB1.25.Revenue of RMB16.54B (+28.5% Y/Y)Press Release For further details see: WuXi AppTec reports FY results
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...